Different subtypes, different evolutionary paths, different treatments possible.
Lung cancer has long worn the face of a smoker's disease, yet between one in ten and one in four diagnoses arrive without that history — a quiet mystery that science has struggled to explain. Researchers at the U.S. National Cancer Institute, publishing in Nature Genetics, have now traced most of these tumors to the body's own interior processes: the slow, inevitable accumulation of mutations that arise from faulty DNA repair and oxidative stress, not from the world outside. By identifying three distinct molecular subtypes — each with its own pace, genetic signature, and vulnerability — the study reframes lung cancer in never-smokers as a condition shaped more by the passage of time within the body than by any single external cause, and opens a path toward treatments as individual as the tumors themselves.
- Lung cancer kills more than two million people each year, and a significant share of those patients never touched a cigarette — a paradox that has left clinicians without a clear explanation or a tailored response.
- A whole-genome study of 232 never-smokers has now shown that the culprit is largely internal: natural cellular processes like oxidative stress and impaired DNA repair, not environmental carcinogens, are writing the mutations that turn healthy lung tissue malignant.
- Three molecularly distinct subtypes have been mapped — a slow-creeping 'piano' variant linked to progenitor cell activation, a faster 'mezzo-forte' driven by EGFR mutations, and a rapidly growing 'forte' marked by full genome duplication — each demanding a different clinical strategy.
- The slow growth of the 'piano' subtype may offer a rare early-detection window, while the concentrated driver mutations in the other two subtypes make them candidates for precisely targeted therapies.
- The study disproportionately concerns women and younger patients, groups who bear an outsized share of never-smoker lung cancer diagnoses and who have historically been underserved by treatment frameworks built around tobacco exposure.
Between one in ten and one in four people diagnosed with lung cancer have never smoked. For decades, that statistic sat uneasily in the medical record — an anomaly without a satisfying explanation. A team led by epidemiologist Maria Teresa Landi at the U.S. National Cancer Institute has now published findings in Nature Genetics that begin to resolve the puzzle, and the answer turns out to be largely written inside the body itself.
The researchers sequenced the full genomes of tumors and healthy tissue from 232 never-smokers diagnosed with non-small-cell lung cancer, the majority of them adenocarcinomas. Matching what they found against a catalog of known mutational fingerprints, they determined that most tumors bore the marks of endogenous damage — natural processes such as oxidative stress and faulty DNA repair — rather than any signature tied to tobacco or secondhand smoke exposure.
The analysis produced something more than a single answer: it revealed three distinct molecular subtypes. The researchers named them in musical terms, scaled to the amount of genomic change each carried. The 'piano' subtype, the most common, harbors the fewest mutations and grows with unusual slowness over many years, linked to the activation of progenitor cells. The 'mezzo-forte' subtype carries mutations in the EGFR gene and specific chromosomal alterations, growing more quickly. The 'forte' subtype features a duplication of the entire genome — a change more often seen in smokers' tumors — and also advances rapidly.
The clinical implications run in different directions for each type. The slow trajectory of 'piano' tumors could give physicians a meaningful window for early detection. The 'mezzo-forte' and 'forte' variants, concentrated around a small number of driver mutations, may be identifiable from a single biopsy and could respond well to targeted therapies. Lung cancer remains the world's leading cancer killer, and it strikes never-smokers with a particular demographic weight — more often women, more often younger patients. By charting the molecular terrain of these tumors, researchers have moved from asking why never-smokers develop lung cancer to asking how each subtype might best be met.
Between one in ten and one in four people diagnosed with lung cancer have never smoked a cigarette. For decades, this fact has puzzled researchers. How does a disease so strongly associated with tobacco develop in people with no smoking history? A team led by scientists at the U.S. National Cancer Institute may have found the answer. Their work, published today in Nature Genetics, reveals that most of these tumors arise not from external carcinogens but from the natural accumulation of mutations that occur inside the body over time.
The study examined 232 never-smokers, predominantly of European descent, who had been diagnosed with non-small-cell lung cancer. Researchers used whole-genome sequencing to map the genetic changes in both tumor tissue and healthy tissue from each patient. The group included 189 adenocarcinomas—the most common form of lung cancer—along with 36 carcinoid tumors and seven others of various types. None of the patients had yet begun cancer treatment.
Using a catalog of known mutational signatures—essentially fingerprints left behind by different cellular processes—the researchers searched the tumor genomes for clues about what had caused the cancer to develop. They found that the vast majority of tumors in never-smokers carried signatures associated with endogenous damage: natural processes occurring within the body, such as faulty DNA repair or oxidative stress. As expected, they found no signatures linked to direct tobacco exposure. Among the 62 patients who had been exposed to secondhand smoke, the researchers also found no such signatures, though they noted the sample size was small and exposure levels varied widely.
The analysis revealed three distinct molecular subtypes of lung cancer in never-smokers, which the researchers named according to musical terminology based on the amount of genetic "noise"—the number of genomic changes—in each tumor. The predominant subtype, called "piano," had the fewest mutations and appeared linked to the activation of progenitor cells, which generate new cells. These tumors grow very slowly over many years, making them difficult to treat despite their low mutation count. The "mezzo-forte" subtype showed specific chromosomal changes and mutations in the EGFR growth factor receptor gene, a gene frequently altered in lung cancer, and exhibited faster tumor growth. The "forte" subtype displayed a duplication of the entire genome, a change often seen in lung cancers of smokers, and also grew rapidly.
Maria Teresa Landi, the epidemiologist who led the study, explained the significance: different subtypes of lung cancer in never-smokers have distinct molecular characteristics and evolutionary patterns. This heterogeneity opens new possibilities for treatment. The slow-growing "piano" subtype might give doctors a window to detect tumors early, when they are easier to treat. The "mezzo-forte" and "forte" subtypes, which have only a few key driver mutations, could potentially be identified from a single biopsy and might respond well to targeted therapies designed for their specific genetic profiles.
Lung cancer remains the leading cause of cancer death worldwide, with more than two million people diagnosed annually. The disease strikes never-smokers differently than smokers: it occurs more frequently in women and at a younger age. Environmental factors—secondhand smoke, radon, air pollution, asbestos, and prior lung disease—explain some cases, but scientists have long been unable to account for the majority. This study begins to fill that gap. By mapping the molecular landscape of these tumors, researchers have moved closer to understanding not just why never-smokers develop lung cancer, but how to treat each type more effectively. The next phase will be translating these molecular insights into clinical practice, tailoring prevention and treatment strategies to match the specific subtype each patient carries.
Citações Notáveis
We're beginning to understand how these tumors evolve. This analysis shows there is heterogeneity in lung cancers among never-smokers.— Maria Teresa Landi, epidemiologist leading the study
A Conversa do Hearth Outra perspectiva sobre a história
Why does lung cancer happen in people who've never smoked? It seems almost unfair.
That's the question researchers have been wrestling with for years. Between 10 and 25 percent of all lung cancers occur in never-smokers, and until now, nobody really understood the mechanism. This new work shows it's not about external exposure—it's about what the body does to itself naturally over time.
What do you mean by natural processes? Aren't those supposed to be safe?
Safe is relative. Your cells are constantly dividing, repairing DNA, managing oxidative stress. Most of the time these processes work fine. But occasionally, mistakes accumulate. In some people, those mistakes eventually add up to cancer. It's not negligence or bad luck—it's just the wear and tear of being alive.
So the study found three different types of this cancer?
Yes, and the names are clever. The "piano" subtype grows slowly, almost imperceptibly, over years. The "mezzo-forte" grows faster and has specific genetic markers. The "forte" is the fastest and looks genetically similar to smoker's lung cancer, even though these patients never smoked. Each one tells a different story about how the tumor evolved.
Does knowing the subtype change how doctors treat it?
That's the hope. A slow-growing tumor might be caught early if you know what to look for. The faster-growing ones have fewer key mutations, so targeted drugs might work better. Right now, doctors treat all never-smoker lung cancers roughly the same way. This research suggests they shouldn't.
What happens next?
The real work begins now—moving from understanding the genetics to actually changing clinical practice. Hospitals will need to test tumors, identify which subtype a patient has, and then match them to the right treatment. It's personalized medicine, but it requires infrastructure and training that doesn't exist everywhere yet.